alexa Optimization of Fc-mediated effector functions of monoclonal antibodies.


Immunotherapy: Open Access

Author(s): Strohl WR

Abstract Share this page

The engineering of therapeutic and clinical candidate monoclonal antibodies and Fc fusion proteins is becoming more sophisticated at generating molecules that are better suited to the pharmacological activity required of them. There are at least 14 marketed and clinical candidate antibodies and Fc fusion proteins in which the Fc has been modified, either via changes in amino acid sequence or in glycoforms. Recent research and development activities in Fc engineering to generate 'fit-for-purpose' antibodies and Fc fusion proteins are reviewed. This article was published in Curr Opin Biotechnol and referenced in Immunotherapy: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version